Abstract:Chimeric antigen receptor T cell (CAR-T) therapy is a late-model of immune cell therapy that has been shown to be effective in refractory/recurrent B-cell leukemia and lymphoma. Compared with the traditional anti-tumor methods, CAR-T cell therapy has the advantages of higher specificity, stronger lethality and longer-lasting efficacy. Although CAR-T cells have made significant progress in the treatment of hematologic malignancies, diverse difficulties remain in the treatment of solid tumors, including immune escape due to tumor antigen heterogeneity, preventing entry or limiting the persistence of CAR-T cells by physical or cytokine barriers and along with other immunosuppressive molecule and cells in the tumor microenvironment (TME). Otherwise, the intracellular signaling of CAR also impact on CAR-T cells persistence. Appropriate modification of intracellular costimulatory molecular signal in the structure of CAR or coexpression of CAR and cytokines can provide a way to enhance CAR-T cells activity. Additionally, CAR-T cells dysfunction due to T cell exhaustion is associated with multi-factors, especially transcription factors, such as c-Jun, NR4A. Engineering CAR-T cells to coexpress or knockout transcription factors in favor of T<sub>CM</sub> memory CAR-T cells differentiation was proved to prolonged the survival of CAR-T cells. Finally, combination of CAR-T cells with oncolytic viruses, nanoparticles or immune checkpoint inhibitors provides an effective measure to improve CAR-T cells function. Here, we discuss all of these advances and challenges and review promising strategies for treating solid tumors. In particular, we also highlight that CAR-T cells have enormous potential to be used in combination with other immunotherapies.

TCR-T Immunotherapy: The Challenges and Solutions

Genetically engineered T cells for cancer immunotherapy

TCR engineered T cells for solid tumor immunotherapy

Progress in T cell receptor-gene engineered T cell immunotherapy for solid tumors

Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy

How does TCR-T cell therapy exhibit a superior anti-tumor efficacy

Targeting cancers through TCR-peptide/MHC interactions

Toward a comprehensive solution for treating solid tumors using T-cell receptor therapy: A review

Clinical advances and challenges associated with TCR-T cell therapy for cancer treatment

Emerging Strategies in TCR-Engineered T Cells

Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu

Innovative Strategies to Advance CAR T Cell Therapy for Solid Tumors.

TCR-engineered T cell therapy in solid tumors: State of the art and perspectives

Obstacles And Coping Strategies Of Car-T Cell Immunotherapy In Solid Tumors

Engineered T-cell Receptor T Cells for Cancer Immunotherapy

Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons

Neoantigen-targeted TCR-T cell therapy for solid tumors: How far from clinical application

Hurdles of CAR-T Cell-Based Cancer Immunotherapy Directed Against Solid Tumors.

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)